This indicates that APRIL CAR-T cell therapy can maintain tumor control in case of BCMA downregulation, which is a well-described tumor escape mechanism in BCMA-directed CAR-T cell studies (94). This evidence concerns the gene TNFRSF17 and neoplasm.